Sanofi India (500674) Q3 2026 earnings summary

Executive summary

• Q3 2026 net sales grew 4% YoY, with domestic sales up 2%; profit before tax (PBT) before exceptional items rose 22% to ₹1,577mn.

• Q3 PAT increased 54% YoY to ₹1,167mn, supported by diabetes growth, favorable product mix and lower operating expenses.

Financial highlights

• Revenue from operations was ₹4,917mn in Q3 2026 vs ₹4,754mn in Q3 2025; 9M revenue was ₹14,017mn vs ₹14,176mn.

• 9M PAT rose to ₹3,028mn from ₹2,650mn; 9M EPS was ₹131.48 vs ₹115.06.

• Q3 total comprehensive income was ₹1,167mn vs ₹760mn YoY; 9M total comprehensive income was ₹3,028mn vs ₹2,650mn.

Outlook and guidance

• Diabetes injectables, a modernized go-to-market model and widening public-sector access were described as foundations for sustainable long-term value creation.

• Strategic partnerships continue to expand commercial reach; performance strengthening remains a focus.